Company Overview
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.
Why Investors Should Care
Trades at a P/E of 8.5, below the sector median of 24.8.
Carries low leverage with a debt-to-equity ratio of 0.06.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | -83.14% |
| 6 Months: | -15.27% |
| 3 Months: | -15.69% |
| 1 Month: | +27.41% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)59.32 · Neutral
P/E of 8.50 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 83.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AZTR Azitra, Inc. PHARMA | 0.17 | 8.50 | $10.30M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 85.00K | 48.50K | 113.30K | 172.00K | 310.70K | 0 | 7.50K | 0 | - | 0 | 0 | - |
| Operating Income | - | -2.09M | -2.37M | -1.56M | -1.43M | -1.99M | -2.96M | -2.66M | -2.93M | -3.10M | -2.87M | -2.77M | -3.93M |
| Net Income | -2.33M | -1.89M | -2.42M | -2.46M | -4.43M | -1.94M | -2.93M | -2.63M | -1.01M | -3.07M | -2.89M | -2.76M | -3.93M |
| Diluted EPS | - | -2.45 | -2.95 | -3.00 | -70.83 | -4.82 | -4.32 | -2.74 | -1.14 | -1.55 | -0.18 | -0.67 | -0.25 |
| R&D Expense | - | 1.51M | 1.36M | 829.03K | 754.95K | 548.52K | 1.47M | 1.12M | 1.02M | 1.25M | 1.40M | 1.18M | 1.56M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 284.00K | 686.00K | 7.50K | 0 |
| Operating Income | -9.45M | -7.45M | -10.99M | -10.97M |
| Net Income | -10.68M | -11.28M | -8.97M | -10.96M |
| Diluted EPS | -12.74 | -54.98 | -15.70 | -2.25 |
| R&D Expense | 6.10M | 3.64M | 4.72M | 4.84M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Jun 2025 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | 7.17M | 5.12M | 7.36M | - | 5.03M |
| Total Equity | -25.77M | -36.26M | 2.91M | 5.70M | 2.20M | 3.80M |
| Cash & Equivalents | - | 3.49M | 1.80M | 4.55M | - | 2.07M |
| Total Liabilities | - | 9.73M | 2.20M | 1.66M | - | 1.22M |
| Current Liabilities | - | 2.22M | 1.60M | 1.38M | - | 1.07M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -8.35M | -7.36M | -10.18M | -11.22M |
| Investing Cash Flow | -336.76K | -318.26K | -379.25K | -182.91K |
| Financing Cash Flow | 4.13M | 5.98M | 13.32M | 8.92M |
| Capital Expenditure | -33.10K | -26.54K | -8.57K | -24.21K |
| Free Cash Flow | -8.38M | -7.39M | -10.19M | -11.25M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | -3,328.7% | -1,086.1% | -146,468.5% | - |
| Net Margin % | -3,760.7% | -1,644.9% | -119,566.6% | - |
| ROE % | 29.5% | -387.3% | -157.4% | -288.2% |
| ROCE % | -191.2% | -212.1% | -183.6% | -277.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Dauntless Investment Group, LLC | 18.63% | 11.29M | $1.96M |
| 2 | Stonepine Capital Management, LLC | 8.72% | 5.29M | $919.67K |
| 3 | Nantahala Capital Management, LLC | 3.65% | 2.21M | $385.17K |
| 4 | Jane Street Group, LLC | 0.41% | 248.43K | $43.23K |
| 5 | Geode Capital Management, LLC | 0.16% | 95.41K | $16.60K |
| 6 | Citadel Advisors Llc | 0.14% | 86.24K | $15.01K |
| 7 | Virtu Financial LLC | 0.11% | 64.94K | $11.30K |
| 8 | UBS Group AG | 0.08% | 50.48K | $8.78K |
| 9 | Stonex Group Inc. | 0.05% | 28.65K | $4.99K |
| 10 | Tower Research Capital LLC (TRC) | 0.03% | 19.50K | $3.39K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AZTR
Initial data on a program targeting fine lines and wrinkles will be shared by Azitra - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOX1MtaWIxbGRHYTJ2Q250Y2RLeDRXWGxkcmZQQmJHdXZwZU9jdkhJTGE4a3F4dGZMa2ZmUzFyVkRvN0gwNjBPSDZiTHd3Z0FYSTI2WWZZRjBEY3M4c0VHa2FFUUhaWjl1ZGxxeDhNNnRmN1BoU1UyUHVwR2dKRXNXdXpKVWZSOG53YU1kd2…
Why Is AZTR Stock Rising Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQU0w4eXl0WDVfalVjZEpfZ3lZeUtTemY5OUtuWVpjZjQ5U3NYVV9vWEJZaFZ2MTVFMmRIel9hZ3NKc3BhTkptT0JWSXFrMFZ1Z18yczREVGV0eUFRVG92cFIxUm9XcEdQN3pQc2VPTkRwN0VVaFVtN3NlTTVwTDRRalk3QVk1dXRlelZjck…
Azitra (NYSE: AZTR) wins back listing under new NYSE watch period - Stock Titan
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPVnA1RWlfejRBVmlFN2RjRUlCOUR4VkJEZnItSjVlUnRzRHhBamsxMS1EYTZPNlVGYlVFVkE1aEJlOUJCWTFublZlY2ExLThOWGJYTEptanE5UnZyTEYwR2hRVC0zcmR4ekhsV2xmeUdqU1BnalpLR3Y1N2oySnNkRUdHd2l3eFdqbFlqQm…
AZTR - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5ESGlhUFVCS3Vaa0pPaGo3U1FkWE9UYXR4UTBKVHlOcW9HRWJTdXBmUWJBN1AxTzF1X2Q5ZmFhbWt2Ukhoc2c?oc=5" target="_blank">AZTR</a> <font color="#6f6f6f">Finviz</font>…
Which stocks are moving after the closing bell on Monday? - ChartMill
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNMnY3d2d0aVJQY3p1aERFZWI3TEhEQ0ZMVTNNOFJmSmQ3Q092bDJFbDVKR245dV9OakF3T0RSUzFtTjNVS1FlbXVya0s0MjhlcDh5Rm9CaTZJR2N6clNzZTRzeHZ4VEhPUGZsWVNJcVRTTUNGRmlJMlVCQklhbE9KbWVsVjVKUjljUFBpdn…
Azitra Regains NYSE American Listing Compliance Status - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxOYzVFcGhNallNWDk1dHpYTVZxSlpOTWdnbF9UbnVxQ3RBWThSQVRoUzlTZ01KWkhJS0l0Y1czVzFXX0lIemlVMDVyN3FCN3BSTUU5cDdVdXduZ3N4VjZGdUdJRkhmSWhHZjhLMHFLVzNrSFN1TlQzVmVNaEJEWG5US3duN3hGbWdzZkJ6eG…
AZTR — Frequently Asked Questions
What is the current share price of Azitra, Inc. (AZTR)?
As of 2026-09-19 21:16 PDT, Azitra, Inc. (AZTR) trades at $0.17 on NYSE American. Its 52-week range is $0.12 to $1.07.
What is the market capitalisation of AZTR?
Azitra, Inc. (AZTR) has a market capitalisation of $10.30M on NYSE American.
What is the P/E ratio of AZTR?
AZTR trades at a trailing price-to-earnings (P/E) ratio of 8.50. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.47.
Is AZTR a good stock to buy?
This page provides a data-driven analysis of Azitra, Inc. (AZTR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.